Citadel Advisors’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-214,664
| Closed | -$571K | – | 15862 |
|
|
2024
Q1 | $571K | Sell |
214,664
-201,178
| -48% | -$498K | ﹤0.01% | 8091 |
|
|
2023
Q4 | $986K | Sell |
415,842
-644,001
| -61% | -$1.14M | ﹤0.01% | 6714 |
|
|
2023
Q3 | $1.48M | Sell |
1,059,843
-26,543
| -2% | -$63.7K | ﹤0.01% | 5786 |
|
|
2023
Q2 | $3.29M | Buy |
1,086,386
+12,837
| +1% | +$49.5K | ﹤0.01% | 4305 |
|
|
2023
Q1 | $6.71M | Sell |
1,073,549
-29,825
| -3% | -$182K | ﹤0.01% | 3344 |
|
|
2022
Q4 | $6.73M | Buy |
1,103,374
+7,073
| +0.6% | +$57.6K | ﹤0.01% | 3394 |
|
|
2022
Q3 | $13.1M | Sell |
1,096,301
-31,088
| -3% | -$407K | ﹤0.01% | 2394 |
|
|
2022
Q2 | $14.2M | Sell |
1,127,389
-5,665
| -0.5% | -$52.7K | ﹤0.01% | 2240 |
|
|
2022
Q1 | $12.8M | Buy |
1,133,054
+11,350
| +1% | +$125K | ﹤0.01% | 2587 |
|
|
2021
Q4 | $19.9M | Sell |
1,121,704
-32,569
| -3% | -$687K | ﹤0.01% | 2031 |
|
|
2021
Q3 | $26.6M | Sell |
1,154,273
-146,614
| -11% | -$3.19M | 0.01% | 1680 |
|
|
2021
Q2 | $30.3M | Sell |
1,300,887
-14,763
| -1% | -$376K | 0.01% | 1605 |
|
|
2021
Q1 | $41M | Buy |
1,315,650
+150
| +0% | +$5.23K | 0.01% | 1220 |
|
|
2020
Q4 | $52.3M | Buy |
+1,315,500
| New | +$52.8M | 0.01% | 921 |
|
Citadel Advisors's KNTE Position: Q2 2024 in Review
Citadel Advisors sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 214,664 shares — an estimated $571K sold.
Citadel Advisors first reported a position in KNTE in Q4 2020 and held it in 14 quarters. The position peaked at $52.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Citadel Advisors reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Citadel Advisors sold 214,664 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $571K.
- Citadel Advisors first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 14 quarters.
- Citadel Advisors's Kinnate Biopharma Inc. Common Stock position peaked at $52.3M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.